Minerva Biotechnologies Corporation announced that its trial of huMNC2-CAR44 T cells has now opened at City of Hope, Duarte, California. This is a first-in-human trial targeting the tumor-associated form of MUC1, called MUC1*, the transmembrane cleavage product that is a growth factor receptor that drives growth of an estimated 93% of breast cancers.
[Minerva Biotechnologies]
7992332
{7992332:AAAAAAAA}
apa
50
1
171696
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/